InSite Vision, Inc.
Product Candidates

DexaSite(ISV-305)

DexaSite (ISV-305) is a DuraSite formulation of 0.1% dexamethasone in Phase 3 clinical development for the treatment of ocular inflammation (e.g., blepharitis). 

DexaSite(ISV-305)

DexaSite (ISV-305) is a DuraSite formulation of 0.1% dexamethasone in Phase 3 development for the treatment of ocular pain and inflammation in cataract surgery.

ISV-101

ISV-101 is a low dose (0.01% to 0.04%) bromfenac ophthalmic solution formulated in DuraSite, which will be evaluated for the treatment of dry eye disease. Following IND filing in the 1st Quarter of 2011, a Phase I/II study investigating several concentrations of bromfenac in DuraSite is planned.

AzaSite Xtra(ISV-405)

AzaSite Xtra(ISV-405) is a higher dose (2.0%) of azithromycin ophthalmic solution formulated in DuraSite. InSite Vision, a SUN PHARMA company has completed all formulation/stability data and all GLP toxicology work to support global IND and/or IND-equivalent filings. AzaSite Xtra will be pursuing a once-daily, three day dosing regimen for the treatment of ocular infections, such as blepharitis, belpharoconjunctivitis, or bacterial conjunctivitis (Pink eye).